(PR NEWSWIRE) Henley Healthcare, Inc. Receives a $30 Million Order From th
Henley Healthcare, Inc. Receives a $30 Million Order From the Indonesian
Government
The Company's Netherlands Based Subsidiary, Enraf-Nonius, B.V., Awarded Major
Project
SUGAR LAND, Texas, July 13 /PRNewswire/ -- Henley Healthcare, Inc.
(Nasdaq: HENL) Tuesday announced that its wholly owned subsidiary, Netherlands
based Enraf-Nonius, B.V., has been selected as a contractor to assist in
providing approximately $30 million of medical equipment and services to
physical therapy and rehabilitation facilities in 54 public hospitals
throughout 23 provinces in Indonesia over an 18 month period.
Financing of the project to the Indonesian government will be provided
pursuant to a subsidy program initiated by the Dutch government. Payment is
guaranteed through the issue of a letter of credit with ABN-Amro Bank in the
Netherlands. The financing of working capital will be provided to Enraf-
Nonius by The Netherlands based, Banque Artesia.
"Throughout the world, the Enraf-Nonius name is synonymous with leading-
edge physical rehabilitation products," said Michael M. Barbour, president and
chief executive officer of Henley Healthcare. "This project validates Henley
Healthcare's strategy of global distribution."
Enraf-Nonius is a worldwide leader in electrotherapy and ultrasound
products based in Delft, The Netherlands. Enraf-Nonius, acquired by Henley
Healthcare, Inc. in May 1998, has been in business for more than 70 years
specializing in the development, manufacture and sale of a complete line of
innovative medical products to the physical therapy and rehabilitation
markets.
Henley Healthcare, Inc., a leader in the growing pain management industry,
develops, manufactures and distributes products and related accessories used
in the control of acute or chronic pain. Henley's diversified line of non-
invasive physical medicine and rehabilitation products are used in the
treatment of disabilities or injuries with therapeutic exercise and the
application of various heat, Fluidotherapy(R), traction, ultrasound or other
modalities.
The Company is also awaiting FDA approval on its MicroLight 830(TM), a
hand-held, low-energy (non-surgical) laser for the treatment of repetitive
stress injuries such as carpal tunnel syndrome. For additional information on
Henley Healthcare, visit their Web site at www.henleyhealth.com.
Forward Looking Statements
Included in this release are "forward -looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Although the Company
believes that the expectations reflected in such forward-looking statements
are reasonable, it can give no assurance that such expectations reflected in
such forward-looking statements will prove to have been correct. The
Company's actual results could differ materially from those anticipated in the
forward-looking statements as a result of certain factors including (i) the
Company's ability to manufacture and market its product profitably, (ii) the
adequacy of funds provided from operations, bank financing and any sales of
equity or debt securities to fund the Company's current operations, (iii) the
Company's ability to complete the integration of its acquired operations, (iv)
the effect of any current or future competitive products, (v) the timely
approval of the Company's product candidates by appropriate governmental and
regulatory agencies, (vi) the retention of key personnel, and (vii) general
capital market conditions. Additional information on these and other factors
that could potentially affect the Company's financial results may be found in
the Company's filings with the Securities and Exchange Commission.
SOURCE Henley Healthcare, Inc.
-0- 07/13/99
/CONTACT: Ronnie V. Shields, Investor Relations of Henley Healthcare,
Inc., 281-276-7000/
/Web site: henleyhealth.com
(HENL)
CO: Henley Healthcare, Inc.; Enraf-Nonius, B.V.
ST: Texas, Indonesia, Netherlands
IN: HEA
SU: CON
*** end of story *** |
